Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies

Endocrine

Volumn 48, Issue 2, 2015, Pages 461-471

  Giorda, Carlo B ^a   Sacerdote, Carlotta ^b   Nada, Elisa ^c   Marafetti, Lisa ^a   Baldi, Ileana ^d   Gnavi, Roberto ^e  

^a ASL TO5   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Chaira Medica Association   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e ASL TO3   (Italy)

Author keywords

Incretins; Meta analysis; Observational studies; Pancreatitis; Type 2 diabetes

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; LINAGLIPTIN; LIRAGLUTIDE; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN;

ACUTE PANCREATITIS; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE ASSOCIATION; HUMAN; INCIDENCE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; PANCREATITIS;

DIABETES MELLITUS, TYPE 2; HUMANS; INCRETINS; OBSERVATIONAL STUDIES AS TOPIC; PANCREATITIS;

EID: 84942303261     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0386-8     Document Type: Article

References (38)

1. C.F. Deacon, E. Mannucci, B. Ahre´n, Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes. Obes. Metab. 14, 762–767 (2012)
2. B. Gallwitz, Extra-pancreatic effects of incretin-based therapies. Endocrine (2014). doi:10.1007/s12020-014-0223-0
3. N. Mikhail, Effects of incretin-based therapy in patients with heart failure and myocardial infarction. Endocrine 47(1), 21–28 (2014). doi:10.1007/s12020-014-0175-4
4. J.A. Koehler, L.L. Baggio, B.J. Lamont, S.D. Ali, D.J. Drucker, Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes. 58, 2148–2161 (2009)
5. J.S. Nachnani, D.G. Bulchandani, A. Nookala, B. Herndon, A. Molteni, P. Pandya, R. Taylor, T. Quinn, L. Weide, L.M. Alba, Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia. 53, 153–159 (2010)
6. K. Tatarkiewicz, P.A. Smith, E.J. Sablan, C.J. Polizzi, D.E. Aumann, C. Villescaz, D.M. Hargrove, B.R. Gedulin, M.G.W. Lu, L. Adams, T. Whisenant, D. Roy, D.G. Parkes, Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am. J. Physiol. Endocrinol. Metab. 299, E1076–E1086 (2010)
7. S.N. Iyer, A.J. Drake, R.I. West, C.E. Mendez, R.J. Tanenberg, Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide. Endocr. Pract. 18, 10–13 (2012)
8. A.S. Franks, P.H. Lee, C.M. George, Pancreatitis: a potential complication of liraglutide? Ann. Pharmacother. 46, 1547–1553 (2012)
9. M. Sue, A. Yoshihara, K. Kuboki, N. Hiroi, G. Yoshino, A case of severe acute necrotizing pancreatitis after administration of sitagliptin. Clin. Med. Insights. Case. Rep. 6, 23 (2013)
10. M. Elashoff, A.V. Matveyenko, B. Gier, R. Elashoff, P.C. Butler, Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 141, 150–156 (2011)
11. J.L. Faillie, S. Babai, S. Crépin, V. Bres, M.L. Laroche, H. Le Louet, P. Petit, J.L. Montastruc, D. Hillaire-Buys, The French Pharmacovigilance Centers Network. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. Acta Diabetol. 51(3), 491–497 (2014)
12. E.A. Gale, GLP-1 based agents and acute pancreatitis: drug safety falls victim to the three monkey paradigm. BMJ. 346, f1263 (2013)
13. C.J. Girman, T.D. Kou, B. Cai, C.M. Alexander, E.A. O’Neill, D.E. Williams-Herman, L. Katz, Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes. Obes. Metab. 12, 766–771 (2010)
14. R.A. Noel, D.K. Braun, R.E. Patterson, G.L. Bloomgren, Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes. Care. 32, 834–838 (2009)
15. A. Gonzalez-Perez, R.G. Schlienger, L.A. Rodríguez, Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. Diabetes. Care. 33(12), 2580–2585 (2010)
16. S.-W. Lai, C.-H. Muo, K.-F. Liao, F.-C. Sung, P.-C. Chen, Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: A population-based cohort study in Taiwan. Am. J. Gastroenterol. 106, 1697–1704 (2011)
17. K.B. Blomgren, A. Sundstrom, G. Steineck, B.E. Wiholm, Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis. Diabetes. Care. 25, 298–302 (2002)
18. F.L. Fimognari, A. Corsonello, R. Pastorell, R. Antonelli-Incalzi, Metformin-induced pancreatitis: a possible adverse drug effect during acute renal failure. Diabetes. Care. 29, 1183 (2006)
19. S. Mallick, Metformin-induced acute pancreatitis precipitated by renal failure. Postgrad. Med. J. 80, 239–240 (2004)
20. C.B. Giorda, E. Nada, B. Tartaglino, Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine 46(3), 406–419 (2014)
21. M. Monami, I. Dicembrini, E. Mannucci, Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes. Obes. Metab. 16(1), 48–56 (2014)
22. B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, P. Hirshberg, R. Frederich, S.D. Wiviott, E.B. Hoffman, M.A. Cavender, J.A. Udell, N.R. Desai, O. Mosenzon, D.K. McGuire, K.K. Ray, L.A. Leiter, I. Raz, the SAVOR-TIMI 53 Steering Committee and Investigators, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369(14), 1317–1326 (2013)
23. W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, G.L. Bakris, A.T. Perez, P.R. Fleck, C.R. Mehta, S. Kupfer, C. Wilson, W.C. Cushman, F. Zannad, the EXAMINE Investigators, Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369(14), 1327–1335 (2013)
24. L.V. Hedges, T.D. Pigott, The power of statistical test in meta-analysis. Psychol. Methods. 6, 203–217 (2001)
25. D.D. Dore, M. Hussein, C. Hoffman, E.M. Pelletier, D.B. Smith, J.D. Seeger, A pooled analysis of exenatide use and risk of acute pancreatitis. Curr. Med. Res. Opin. 29(12), 1577–1586 (2013)
26. D.D. Dore, G.L. Blomgren, M. Wenten et al., A cohort study of acute pancreatitis in relation to exenatide use. Diabetes. Obes. Metab. 13(6), 559–566 (2011)
27. M. Wenten, J.A. Gaebler, M. Hussein, E.M. Pelletier, D.B. Smith, P. Girase, R.A. Noel, D.K. Braun, G.L. Bloomgren, Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet. Med. 29(11), 1412–1418 (2012)
28. D.D. Dore, D. John, J.D. Seeger, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr. Med. Res. Opin. 25(4), 1019–1027 (2009)
29. R. Garg, W. Chen, M. Pendergrass, Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes. Care. 33(11), 2349–2354 (2010)
30. J.A. Romley, D.P. Goldman, M. Solomon, D. McFadden, A.L. Peters, Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes. Technol. Ther. 14(10), 904–911 (2012)
31. S. Singh, H.Y. Chang, T.M. Richards, J.P. Weiner, J.M. Clark, J.B. Segal, Glucagon-like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA. Intern. Med. 173(7), 534–539 (2013)
32. C.B. Giorda, R. Picariello, E. Nada, B. Tartaglino, L. Marafetti, G. Costa, R. Gnavi, Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study. www.thelancet.com/diabetes-endocrinology. Accessed 12 Nov 2013. doi:10.1016/S2213-8587(13)70147-5
33. M. Monami, I. Iacomelli, N. Marchionni, E. Mannucci, Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr. Metab. Cardiovasc. Dis. 20, 224–235 (2010)
34. E. Raschi, C. Piccinni, E. Poluzzi, G. Marchesini, F. De Ponti, The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA. Acta Diabetol. 50(4), 569–577 (2013)
35. M.A. Nauck, J.J. Meier, A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes. Care. 36, 2126–2132 (2013)
36. M.A. Nauck, J.J. Meier, Pancreatitis and incretin-based drugs: clarity or confusion? Comment. www.thelancet.com/diabetes-endocrinology. Accessed 12 Nov 2013. doi:10.1016/S2213-8587(13)70186-4
37. L. Frulloni, C. Lunardi, R. Simone et al., Identification of a novel antibody associated with autoimmune pancreatitis. N. Engl. J. Med. 361, 2135–2142 (2009)
38. H.M. Lando, M. Alattar, A.P. Dua, Elevated amylase and lipase levels in patients using glucagon-like peptide-1 receptor agonists or dipeptidyful-peptidase-4 inhibitors in the outpatient setting. Endocr. Pract. 18, 472–477 (2012)